Could the eased telehealth restrictions implemented in response to the COVID-19 pandemic allow for greater access to dermatologic care? We sat down with experts to explore how telehealth could be used to expand quality care to vulnerable and underserved populations across the United States.
Researchers conducted a population-based study examining a sample of patients with HS during hospital admissions.
Linda Stein-Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight…
Desai emphasized that most dermatologists would rather biopsy a potential melanoma than miss one that could become deadly.
In online discussion April 23,commissioners cited health care specifically among their reasons for supporting the ban.
A review found that Mohs micrographic surgery and conventional excision yielded comparable patient reported outcomes.
At present, deployed members of the military are not permitted to be receiving therapy with systemic therapies such as immunomodulators and biologics.
In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.
Posters from the Academy of Managed Care Pharmacy annual meeting featured studies on atopic dermatitis.
Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.
Chinese clinical researchers recently presented a unique case of JLIS manifesting as erythematous papules and infiltrative plaques on the nose and upper jaw, resembling rosacea.
